AstraZeneca: two drugs approved in Japan
(CercleFinance.com) - This morning AstraZeneca announced that Tezspire (tezepelumab) has been approved by the Japanese health authorities as a treatment for asthma in patients whose disease symptoms cannot be controlled with inhaled corticosteroids and other long-term maintenance therapies.
The Japanese health authorities relied on a phase III study, in which Tezspire demonstrated superiority over placebo on all key primary and secondary endpoints, the group said.
Through clinical trials, Tezspire has demonstrated significant results in a large population of severe asthma patients, and with this approval, physicians can now offer patients in Japan a significant new treatment option, a related medical professional said.
In addition, AstraZeneca reports that Koselugo (selumetinib) has also been approved in Japan for the treatment of patients as from 3 years old with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms (such as pain and disfigurement) and PNs that cannot be completely removed surgically without risk of significant morbidity.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The Japanese health authorities relied on a phase III study, in which Tezspire demonstrated superiority over placebo on all key primary and secondary endpoints, the group said.
Through clinical trials, Tezspire has demonstrated significant results in a large population of severe asthma patients, and with this approval, physicians can now offer patients in Japan a significant new treatment option, a related medical professional said.
In addition, AstraZeneca reports that Koselugo (selumetinib) has also been approved in Japan for the treatment of patients as from 3 years old with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms (such as pain and disfigurement) and PNs that cannot be completely removed surgically without risk of significant morbidity.
Copyright (c) 2022 CercleFinance.com. All rights reserved.